Abstract:As a powerful tool for genome-wide gene expression analysis, DNA microarray technology is widely used in biomedical research. One important application of microarrays is to identify differentially expressed genes (DEGs) between two distinct biological conditions, e.g. disease versus normal or treatment versus control, so that the underlying molecular mechanism differentiating the two conditions maybe revealed. Mechanistic interpretation of microarray results requires the identification of reproducible and reliable lists of DEGs, because irreproducible lists of DEGs may lead to different biological conclusions. Many vendors are providing microarray platforms of different characteristics for gene expression analysis, and the widely publicized apparent lack of intra- and cross-platform concordance in DEGs from microarray analysis of the same sets of study samples has been of great concerns to the scientific community and regulatory agencies like the US Food and Drug Administration (FDA). In this chapter, we describe the study design of and the main findings from the FDA-led MicroArray Quality Control (MAQC) project that aims to objectively assess the performance of different microarray platforms and the advantages and limitations of various competing statistical methods in identifying DEGs from microarray data. Using large data sets generated on two human reference RNA samples established by the MAQC project, we show that the levels of concordance in inter-laboratory and cross-platform comparisons are generally high. Furthermore, the levels of concordance largely depend on the statistical criteria used for ranking and selecting DEGs, irrespective of the chosen platforms or test sites. Importantly, a straightforward method combining fold-change ranking with a non-stringent P-value cutoff produces more reproducible lists of DEGs than those by t-test P-value ranking. Similar conclusions are reached when microarray data sets from a rat toxicogenomics study are analyzed. The availability of the MAQC reference RNA samples and the large reference data sets provides a unique resource for the gene expression community to reach consensus on the "best practices" for the generation, analysis, and applications of microarray data in drug development and personalized medicine.

The Microarray Data Analysis Process:from Raw Data to Biological Significance

Approaches and Practical Considerations for the Analysis of Toxicogenomics Data

A Practical Guide for DNase-seq Data Analysis: from Data Management to Common Applications

Common Meta-Analysis Methods of Microarray Data

The Application of Novel Multifunctional Microarray Slides for Immobilization Biomolecules

Microarrays: Technologies and Applications

Microarray Expression Profiling: Analysis and Applications.

A New Method for Analyzing Gene Expression Data

Data mining techniques for microarray datasets

Dna microarray image processing

Analyzing Microarray Data with Classification and Clustering Methods.

The Microarray Quality Control (Maqc) Project And Cross-Platform Analysis Of Microarray Data

Dna Microarrays: Applications, Future Trends, And The Need For Standardization

QA/QC: challenges and pitfalls facing the microarray community and regulatory agencies.

cDNA Microarray Experiment: Design Issues in Early Stage and the Need of Normalization

Microarray data normalization and transformation

Reproducible and Reliable Microarray Results Through Quality Control: Good Laboratory Proficiency and Appropriate Data Analysis Practices Are Essential

Listen to Genes: Dealing with Microarray Data in the Frequency Domain

Assessment of Data Processing to Improve Reliability of Microarray Experiments Using Genomic DNA Reference.

Microarray Technology: Unresolved Issues And Future Challenges From A Regulatory Perspective

Data Preprocessing of Microarray Gene Expression Profile